Effectiveness of local injection of lentivirus-delivered stathmin1 and stathmin1 shRNA in human gastric cancer xenograft mouse

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 9, 2014, Pages 1685-1691

  Akhtar, Javed ^a   Wang, Zhou ^a   Yu, Che ^a   Zhang, Zhi Ping ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Gastric cancer; Lentivirus; Posttranscriptional gene silencing (PTGS); RNA interference; shRNA; Stathmin; Tumor xenograft model

Indexed keywords

ANTINEOPLASTIC AGENT; LENTIVIRUS VECTOR; MESSENGER RNA; PHOSPHATE BUFFERED SALINE; PROTEIN; SHORT HAIRPIN RNA; STATHMIN; STATHMIN1; UNCLASSIFIED DRUG; SMALL INTERFERING RNA; STMN1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL THERAPY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; INOCULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; GENE THERAPY; GENE VECTOR; GENETICS; INTRALESIONAL DRUG ADMINISTRATION; LENTIVIRINAE; NUDE MOUSE; PROCEDURES; STOMACH NEOPLASMS; THERAPEUTIC USE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; GENETIC THERAPY; GENETIC VECTORS; HETEROGRAFTS; HUMANS; INJECTIONS, INTRALESIONAL; LENTIVIRUS; MALE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RNA, SMALL INTERFERING; STATHMIN; STOMACH NEOPLASMS;

EID: 84906516445     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12594     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ward E, Ferlay J, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013; 63: 11-30.
3. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br. J. Cancer 2000; 83: 311-318.
4. Chen G, Wang H, Gharib T etal. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol. Cell. Proteomics 2003; 2: 107-116.
5. Melhem R, Strahler J, Hailat N, Zhu X, Hanash S. Involvement of OP18 in cell proliferation. Biochem. Biophys. Res. Commun. 1991; 179: 1649-1655.
6. Friedrich B, Gronberg H, Landstrom M, Gullberg M, Bergh A. Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 1995; 27: 102-109.
7. Akhtar J, Wang Z, Yu C, Zhang ZP, Bi MM. STMN-1 gene: a predictor of survival in stage IIA esophageal squamous cell carcinoma after ivor-lewis esophagectomy? Ann. Surg. Oncol. 2014; 21: 315-321.
8. Sobel A. Stathmin: a relay phosphoprotein for multiple signal transduction. Trends Biochem. Sci. 1991; 16: 301-305.
9. Akhtar J, Wang Z, Zhang ZP, Bi MM. Lentiviral-mediated RNA interference targeting stathmin1 gene in human gastric cancer cells inhibits proliferation in vitro and tumor growth in vivo. J. Transl. Med. 2013; 11: 212.
10. Elbashir MS, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001; 15: 188-200.
11. Cogonia C, Macinoa G. Post-transcriptional gene silencing across kingdoms. Curr. Opin. Genet. Dev. 2000; 10: 638-643.
12. Gura T. A silence that speaks volumes. Nature 2000; 404: 804-808.
13. Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nat. Rev. Genet. 2001; 2: 110-119.
14. Song E, Lee S-K, Dykxhoorn DM etal. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J. Virol. 2003; 77: 7174-7181.
15. Yano J, Hirabayashi K, Nakagawa S-I etal. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 2004; 10: 7721-7726.
16. Flynn MA, Casey DG, Todryk SM, Mahon BP. Efficient delivery of small interfering RNA for inhibition of IL-12p40 expressio. J. Inflamm. 2004; 1: 4.
17. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006; 13: 541-552.
18. Oha Y-K, Park TG. siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 2009; 61: 850-862.
19. Howard KA, Rahbek UL, Liu X etal. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 2006; 14: 476-484.
20. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 2005; 11: 50-55.
21. Zhang X, Shan P, Jiang D etal. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. 2004; 279: 10677-10684.
22. Dorn G, Patel S, Wotherspoon G etal. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 2004; 32: e49.
23. Querbes W, Ge P, Zhang W etal. Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes. Oligonucleotides 2009; 19: 23-29.
24. Kuo M-F, Wang H-S, Kuo Q-T etal. High expression of stathmin protein predicts a fulminant course in medulloblastoma. J Neurosurg Pediatr 2009; 4: 74-80.
25. Kouzu Y, Uzawa K, Koike H etal. Overexpression of stathmin in oral squamous-cell carcinoma:correlation with tumour progression and poor prognosis. Br. J. Cancer 2006; 94: 717-723.
26. Saal LH, Johansson P, Holm K etal. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl Acad. Sci. U.S.A. 2007; 104: 7564-7569.
27. Golouh R, Cufer T, Sadikov A etal. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res. Treat. 2008; 110: 317-326.
28. Lin W-C, Chen S-C, Hu F-C etal. Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology 2009; 74: 1264-1269.
29. Su D, Smith SM, Preti M etal. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009; 115: 2453-2463.
30. Chen J, Abi-Daoud M, Wang A etal. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene 2012; 32: 1330-1337.
31. Xi W, Rui W, Fang L, Ke D, Ping G, Hui-Zhong Z. Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J. Cancer Res. Clin. Oncol. 2009; 135: 837-846.
32. Trovik J, Wik E, Stefansson IM etal. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin. Cancer Res. 2011; 17: 3368-3377.
33. Manjunath N, Wu H, Subramanya S, Shankar P. Lentiviral delivery of short hairpin RNAs. Adv. Drug Deliv. Rev. 2009; 61: 732-745.
34. Guo X, Wang W, Hu J etal. Lentivirus-mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo. Anat. Rec. (Hoboken) 2012; 295: 2114-2121.
35. Feng Y, Hu J, Ma J etal. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. Eur. J. Cancer 2011; 47: 2353-2363.
36. Pozzi V, Sartini D, Morganti S etal. RNA-mediated gene silencing of nicotinamide N-methyltransferase is associated with decreased tumorigenicity in human oral carcinoma cells. PLoS One 2013; 8: e71272.
37. Abbas-Terki T, Blanco-Bose W, Déglon N, Pralong W, Aebischer P. Lentiviral-mediated RNA interference. Hum. Gene Ther. 2002; 13: 2197-2201.
38. Stewart SA, Dykxhoorn DM, Palliser D etal. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003; 9: 493-501.
39. Koutsilieri E, Rethwilm A, Scheller C. The therapeutic potential of siRNA in gene therapy of neurodegenerative disorder. J. Neural Transm. Suppl. 2007; 72: 43-49.
40. Gaither A, Iourgenko V. RNA interference technologies and their use in cancer research. Curr. Opin. Oncol. 2007; 19: 50-54.
41. Sherbet GV, Cajone F. Stathmin in cell proliferation and cancer progression. Cancer Genomics Proteomics 2005; 2: 227-238.
42. Samuel-Abraham S, Leonard J. Staying on message: design principles for controlling nonspecific responses to siRNA. FEBS J. 2010; 277: 4828-4836.
43. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009; 8: 129-138.
44. Sørensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 2003; 327: 761-766.
45. Lorenza C, Hadwigera P, Johna M, Vornlochera H-P, Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 2004; 14: 4975-4977.
46. Sioud M, Sørensen DR. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 2003; 312: 1220-1225.